A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants
Status:
COMPLETED
Trial end date:
2024-06-06
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 1a study is to evaluate safety, tolerability, and pharmacokinetics (PK) of single, ascending doses of CS-1103, administered by intravenous (IV) infusion in healthy participants.